Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

NCT06834074 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
ALK-positive Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: NVL-655

Sponsor

Nuvalent Inc.